Calliditas Therapeutics to Unveil Key Findings at Nephrology Congress Calliditas Therapeutics AB will showcase pivotal findings from the Phase 3 NefIgArd trial at the World Congress of Nephrology, shedding light on advances in IgA nephropathy treatment.

Calliditas Therapeutics to Unveil Key Findings at Nephrology Congress #Japan #Yokohama #Calliditas #TARPEYO #NefIgArd

Calliditas Therapeutics Showcases Groundbreaking Research at ASN Kidney Week 2025 Calliditas Therapeutics announces key data on IgAN and Alport Syndrome presented at the American Society of Nephrology Kidney Week, highlighting advancements in nephrology.

Calliditas Therapeutics Showcases Groundbreaking Research at ASN Kidney Week 2025 #USA #Houston #Calliditas #Alport_Syndrome #TARPEYO

Calliditas Therapeutics Unveils Promising Insights at the 62nd European Renal Association Congress Calliditas Therapeutics presented new data at the ERA Congress, showcasing findings from the Phase 3 NefIgArd study on Nefecon for IgA nephropathy

Calliditas Therapeutics Unveils Promising Insights at the 62nd European Renal Association Congress #Sweden #Stockholm #IgA_nephropathy #NEFECON #Calliditas

“We are convinced that our commitment to #SweDeliver will generate mutual value” states Christian Pedersen, Senior Scientist at #Calliditas Therapeutics that recently joined as #industrial #partner number 14 in the international research center ✅ Read full story 👉 www.uu.se/institution/...